La première thérapie génique pour les pathologies neurologiques courantes reçoit l'approbation de l’IND par la FDA – EG 427 lance la première étude clinique chez l'homme
24. Juni 2024 02:00 ET
|
EG 427
EG110A obtient l'autorisation d’entrée en essais cliniques (IND) pour son étude de phase 1b/2a chez les patients souffrant de vessie neurogène.La vessie neurogène est une affection sévère de la vessie...
First gene therapy for prevalent pathologies in neurology receives FDA IND clearance - EG 427 initiating first-in-human clinical study
24. Juni 2024 02:00 ET
|
EG 427
EG110A to start Phase 1b/2a clinical study in Neurogenic Detrusor Overactivity (NDO) patients NDO is a severe bladder condition affecting millions of patients living with Spinal Cord Injury, Multiple...
EG427 Announces New Preclinical Results from Multiple Studies of EG110A in Neurogenic Detrusor Overactivity (NDO) and Overactive Bladder (OAB)
04. Januar 2024 08:00 ET
|
EG 427
EG427 Announces New Preclinical Results from Multiple Studies of EG110A in Neurogenic Detrusor Overactivity (NDO) and Overactive Bladder (OAB) In a non-clinical pharmacology study in an OAB model,...
EG 427 announces final Series A closing, achieving €18 million in total funds raised
13. Juli 2023 02:00 ET
|
EG 427
Paris, France, 13 July, 2023 – EG 427, a biotechnology company leading the development of pinpoint DNA medicine solutions, announces today the final closing of a Series A financing. EG 427 raised an...
EG 427 announces issuance of the first 2 patents for its HSV-based gene therapy treatment
11. April 2023 08:00 ET
|
EG 427
Issued European and Japanese patents cover herpes simplex virus (HSV) vectors selectively inhibiting subtype of sensory neuronsRelated initial therapeutic indications encompass multiple bladder...
EG 427 Appoints New Members To Board of Directors and Scientific Advisory Board
27. März 2023 08:00 ET
|
EG 427
Venture and pharmaceutical industry veteran, Sundar Kodiyalam, becomes a new member on Board of Directors. Leading expert in herpes virus vector research, Gregory A. Smith, Ph.D., joins Scientific...
EG 427 appoints Cornelia Haag-Molkenteller, M.D., Ph.D., as Chief Medical Officer
29. November 2022 05:00 ET
|
EG 427
PARIS, Nov. 29, 2022 (GLOBE NEWSWIRE) -- EG 427, a biotechnology company leading the development of pinpoint gene therapy solutions based on its unique non-replicative HSV-1 vector platform,...
EG 427 appoints Grzegorz Sarek, Ph.D., as Vice President of Research
14. September 2021 01:00 ET
|
EG 427
PARIS, Sept. 14, 2021 (GLOBE NEWSWIRE) -- EG 427, a biotechnology company leading the development of pinpoint gene therapy solutions by using a unique HSV-1 vector platform, today announced the...
EG 427 announces €12 million Series A financing to advance its HSV-1 based gene therapy
01. März 2021 08:00 ET
|
EG 427
David Lamond and Stephane Boissel join the company’s board of Directors PARIS, March 01, 2021 (GLOBE NEWSWIRE) -- EG 427, a biotechnology company developing pinpoint gene therapy, today announced...